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HEPATITIS C RISK FACTORS IN A CAMBODIAN AMERICAN 
 
POPULATION IN LOWELL, MASSACHUSETTS 
 
CATHERINE YU 
 
ABSTRACT 
Background:  Hepatitis C (HCV) is the most common chronic blood-borne 
infection in the US5,6 and has life-threatening complications.10,11,18,27,44  HCV 
rates in Cambodian Americans are as high as national rates,5,11,22,37,41  but the 
transmission risks for Cambodians in the US are unclear.  Rates of drug use, the 
most common national transmission risk,3,6,21 are not as high in this 
population.14,21  With the second largest population of Cambodians nationally, 
Lowell, Massachusetts12,19 provides a unique opportunity to study the risk factors 
associated with  HCV transmission. 
Objective:  The objective of this study is to examine the risk factors 
associated with HCV in Cambodian Americans.  The hypothesis is that HCV 
infected Cambodian Americans will have different rates of the United States 
Preventive Services Task Force (USPSTF) recognized risk factors compared to 
HCV infected non-Cambodian Americans.28   
Methods:  This is a cross sectional study of HCV infected Cambodian and 
non-Cambodian Americans.  Medical record data were abstracted for adults with 
reactive HCV antibody or RNA virus testing at Lowell Community Health Center 
(LCHC) between 2009 and 2012.  Information regarding USPSTF-designated 
HCV risk factors was collected, and a comparison was made of HCV risk factors 
	  vii 
between infected Cambodian and non-Cambodian Americans.  
Results: Cambodian Americans with HCV (n=128) were older (mean age 53 
vs. 43 years old) and less likely to be male (41%) than the non-Cambodian group 
(67% male, n=541).  Cambodians had far lower rates of overall recreational drug 
use (2.3% vs. 82.1%) and intravenous drug use (1.6% vs. 33.6%).  The 
predominant HCV risk factor in Cambodians was birth between 1945 and 1965, 
while that for non-Cambodians was drug use.     
Conclusion: Most HCV infected Cambodian Americans treated at LCHC 
between 2009 and 2012 lacked any history of drug use.  In contrast, the major 
risk factor for HCV infected non-Cambodian Americans treated at LCHC was 
drug use, consistent with the major risk factor for HCV transmission 
nationwide.3,6,21  This suggests that the current major HCV risk factors fail to 
describe how this virus was transmitted to Cambodian Americans who seek care 
at LCHC. 
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Introduction 
Hepatitis C (HCV) is a serious systemic viral infection with potentially fatal 
consequences that include cirrhosis and hepatocellular carcinoma.27  A 2010 
surveillance of viral hepatitis in the United States (US) also noted the high 
mortality associated with this infection.  In 2008, of the three most common viral 
hepatitides (hepatitis A, B, and C), death rates were highest among persons 
infected with hepatitis C (4.7 deaths per 100,000 population).11  From 1999 to 
2007 the numbers of hepatitis C related deaths exceeded deaths due to HIV in 
the US.  HCV related deaths increased to 15,106 for 2007 while HIV related 
deaths that year dropped to 12,734.11,25    In addition, HCV associated liver 
disease remains the leading indication for liver transplant in the 
US.10,18,44   These medical and financial burdens lend significance to the 
seriousness of HCV infection. 
The modes of HCV transmission involve exposure to blood and bodily 
fluids.  The specific nature of the transmission risk, however, can greatly differ 
amongst different population groups.  For example, the risk factors for HCV 
include specific behaviors and exposures by which blood-borne transmission can 
occur, and the major risk in the US is intravenous drug 
use.3,27,29,34,42  Nationwide, 43–60% of HCV infections are due to intravenous 
drug use.3,6,21  However, in many developing countries outside of the US, the 
most frequently identified mode of HCV transmission is through poor hygiene in 
medical practices.24  In these countries, intravenous drug use is not as prominent 
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a risk for HCV transmission.14,21,34   
Even within the US, rates of HCV transmission risks in Asian-Americans, 
whether of Cambodian origin or not, may differ greatly from those of Americans 
who are not ethnically Asian.  Studies have found that HCV-infected Asian 
Americans have rates of drug use that are less than 4%,14,21  compared to 
between 43–60% among HCV-infected non-Asian Americans.14,21  These studies 
also suggest previous “unsafe therapeutic injections” are the most common 
source of HCV infection in HCV infected Asian Americans.14,21   This description 
of HCV transmission for Asians in America is very similar to the transmission 
risks noted for Asians from unhygienic medical practices outside of the US.14,21   
These unhygienic medical practices would be the “reusage of unsterilized 
needles and syringes”,14 “reusable or contaminated surgical equipment during 
routine medical or dental care, acupuncture”, and “mass immunization”.21   At a 
minimum, this suggests that risks for HCV transmission are not the same in 
every population.  Studies of HCV risk factors have included many Asian 
Americans who are mostly not of Cambodian origin, and have not included 
Cambodian Americans in large numbers.11,14,21,22,37  Lowell, Massachusetts has 
the second largest population of Cambodian Americans in the US,12,19 which 
provides an opportunity for an examination of the risks for hepatitis C 
transmission among Cambodian Americans that is larger than has been 
published previously.11,14,21,22,37  
The objective of this study is to assess the risk factors associated with 
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hepatitis C infection in a population of Cambodian Americans compared with 
non-Cambodian Americans receiving care in a large urban health center.  
Cambodian Americans have been found to have comparable rates of hepatitis C 
infection11,22,37 to the general American population,5,41 but the prevalence of 
injection drug use, the major risk factor for hepatitis C infection in the US,29,34,41  
is significantly lower among Cambodian Americans.14,21,34  Thus, my hypothesis 
is that Cambodian American adults who have hepatitis C will have different rates 
of nationally recognized and guideline-sanctioned risk factors for HCV 
transmission than non-Cambodian Americans infected with HCV. This is 
important to examine, as it is crucial to recognize and understand how different 
populations have different rates of transmission risks in order for disease 
identification to be more complete.  Furthermore, this can assist in setting policy 
to tailor screening recommendations for different ethnic subpopulations of US 
residents. 
Background 
Hepatitis C Virus 
According to data from the third National Health and Nutrition Examination 
Survey (NHANES III), the prevalence of HCV infection is estimated to be 1.8% of 
the US population.5,41  At this prevalence rate, HCV remains the most common 
chronic blood-borne infection nationally.5,6  Acute HCV can resolve 
spontaneously, but in 50–85% of cases, infection persists indefinitely.7,9,26,31,40  
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The US Preventive Services Task Force (USPSTF) defines chronic HCV 
infection as “the presence of HCV RNA in the blood for at least 6 months after 
acute infection”.28  Chronic infection has serious medical implications as noted 
above and is the leading indication for liver transplantation in the US and in 
Europe.13  While there are few estimates of hepatitis C prevalence specifically in 
Cambodian Americans; prevalence rates vary from 1.3% to 6% in a variety of 
studies examining hepatitis C in Asian Americans of multiple ethnicities, mostly 
non-Cambodian.11,22,37  Thus, Asian Americans carry similar rates of HCV 
infection compared to the rest of the U.S., and the lifelong consequences of HCV 
infection are serious and chronic, making hepatitis C a significant concern among 
Cambodian Americans. 
 
Risk Factors 
There are currently three major sets of US guidelines that identify risk 
factors for HCV transmission.  These guidelines have been issued by: 1) the 
American Association for the Study of Liver Diseases (AASLD), Infectious 
Diseases Society of America (IDSA), and the International Antiviral Society-USA 
(IAS-USA) jointly,1,17  2) the Centers for Disease Control and Prevention 
(CDC),6,34,43 and 3) the US Preventive Services Task Force (USPSTF).28  While 
the three sets of guidelines have many similarities, there are some notable 
differences.  Each authority’s set of risk factors for HCV is outlined in Table 1 and 
described below.   
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Table 1. HCV Risk Factors by Professional Groups 
 
Group      
AASLD/IDSA/IAS-USA1,17 CDC6,34,43 USPSTF28 
Intravenous drug use  Intravenous drug use Intravenous drug use 
Born between 1945–1965 Born between 1945–1965 Born between 1945–1965 
Transfusion or transplant 
  Donor later test +HCV 
  Before July 1992 
  Clotting factor before 1987 
Transfusion or transplant 
  Donor later test +HCV 
  Before July 1992 
  Clotting factor before 1987 
Blood transfusion before 
1992 
Long term hemodialysis Long-term hemodialysis Long-term hemodialysis 
Birth to HCV+ mother Birth to HCV+ mother Birth to HCV+ mother 
Health care, emergency 
   medical, public safety  
   worker after needle stick, 
   sharp, or mucosal 
   exposure to HCV     
Health care, emergency 
   medical, public safety  
   worker after needle stick, 
   sharp, or mucosal 
   exposure to HCV     
Percutaneous exposure  
   (Health care workers,  
   Surgery before  
   universal precautions) 
Incarceration   Incarceration 
Intranasal drug use   Intranasal drug use 
Tattoo in unregulated setting   Tattoo in unregulated setting    
Persistently abnormal ALT Persistently abnormal ALT   
HIV HIV   
	  
	   	  
6 
	  
	  
AASLD/IDSA Joint Statement 
The AASLD and the IDSA collaborate with the International Antiviral 
Society-USA (IAS-USA) to maintain web-based HCV diagnosis and treatment 
guidelines which are regularly updated.1,17  The major HCV risk factor identified 
in this statement is intravenous drug use.  Also listed are: intranasal illicit drug 
use; incarceration; long term hemodialysis; tattoos received in unregulated 
settings; birth to HCV infected mothers; transfusion or transplant of donated 
material before July 1992 or from donors later found to be HCV positive; 
transfusion with clotting factor concentrate before 1987; HIV; elevated 
aminotransaminase levels, specifically alanine aminotransferase (ALT); and 
being a health care worker who has sustained a needle stick or mucosal 
exposure to HCV.17  In January, 2015, the AASLD/IDSA/IAS-USA joint statement 
also added a year of birth between 1945 and 1965 as a risk for HCV infection. 1,17 
 
CDC Guidelines 
In 2012, the CDC issued guidelines listing the following risk factors for 
HCV transmission.  These factors are intravenous drug use, clotting factor 
transfusion before 1987, long-term hemodialysis, abnormal aminotransferase 
levels, HIV, transfusions or transplants from a donor who was later found to have 
HCV, or recipients of these donations before July 1992, health care work with 
possible percutaneous exposure to HCV, birth to HCV positive mothers, and a 
year of birth between 1945 and 1965.34,43 
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USPSTF Guidelines 
In 2013, the USPSTF issued a set of recommendations for HCV testing to 
update guidelines from 2004.  This set of guidelines listed the risk factors for 
HCV to be:  intravenous drug use, any blood transfusion before 1992, any use of 
long-term hemodialysis, having been born to an HCV infected mother, 
incarceration, intranasal drug use, tattoos in unregulated settings, and 
percutaneous exposures through health care work or surgery before the 
institution of universal precautions.  In 2012, the USPSTF added year of birth 
between 1945 and 1965 to the list of risk factors.28  This is a significant change 
from the previous 2004 USPSTF guidelines, as these guidelines did not strongly 
recommend cohort screening for HCV.28,38    
 
Summary of risks 
The three sets of guidelines described above list many of the same risk 
factors, but there are also a few differences.  The risk factors that are shared by 
these guidelines are intravenous drug use, birth between 1945–1965, long-term 
hemodialysis, health care work, birth to an HCV infected mother, and transfusion 
or transplant before 1992.  The factors that are not shared by all three guidelines 
are HIV infection, aminotransferase abnormalities, intranasal drug use, 
unregulated tattoos, and incarceration.  In the methods section, the risk factors 
assessed in this study will be identified and discussed. 
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Conceptual Model  
  A conceptual model describes the relationship between population 
characteristics and a health condition such as infection with HCV.  The model 
below specifies the characteristics that could be HCV risk factors and the 
relationship of these factors with HCV infection for Cambodian and non-
Cambodian Americans. 
 
Solar and Irwin Conceptual Framework.  
The Solar and Irwin Conceptual Framework on the Social Determinants of 
Health in Figure 1 models the factors that affect how a medical condition is 
distributed within a population.36   
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Figure 1: Based on Solar, O and Irwin, A. A conceptual framework for action on the 
social determinants of health. Discussion paper for the Commission on Social 
Determinants of Health. Geneva: World Health Organization; 200736  
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In this model, Structural Determinants are population characteristics from 
a Social, Economic, or Political context that strongly predict the Social Positions 
of individuals in that population.  The Social Positions are defined by the 
education level, the form of occupation, the income level, the gender, and the 
ethnicity or race.  This Social Position acts through Intermediary Determinants to 
affect the distribution of a health condition.  Intermediary Determinants include 
material circumstances, social cohesion, behaviors, biological factors, and 
psychosocial factors.  These determinants interact with the available health care 
system36 and lead to a health condition of concern.  The differences in how 
populations are exposed to hepatitis C can then be evaluated by comparing the 
Structural and Intermediary Determinants between the groups.   
 
Adaptation of Framework for HCV Transmission 
The application of the Solar and Irwin Conceptual Framework to HCV risk 
factors involves refinement of the Determinants to apply directly to this health 
condition.  Socioeconomic and Political Structural Determinants encompass 
health policy, governmental regulations, and cultural norms as they relate to HCV 
exposure.  Health policies and governmental regulations, when enacted, can 
reduce known HCV risks on a large scale.  Examples of these policies include 
the regulation of tattoo parlors and the screening of blood and organ donations.  
Cultural norms describe a belief system that frames an understanding of disease 
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and acceptance of health policy mandates.  For example, an American cultural 
norm would be the acceptance of routine pediatric appointments for well-child 
visits or the belief that disease transmission can be understood through science.  
These cultural norms and governmental policy interact to strongly influence how 
Social Position is shaped.   
Social Positions describe an individual’s standing in their community.  This 
position is determined by levels of education, occupation, income, gender, and 
ethnicity.  These characteristics can be adjusted for better relevance to HCV 
infection.  Education includes an understanding of disease and how HCV can be 
transmitted.  Certain occupations also serve as an HCV risk, such as health care 
work or public safety work that involves percutaneous HCV exposures.  Gender, 
Ethnicity, and the level of financial stability define an individual’s identity and 
susceptibility to HCV exposures.  Age affects an individual’s social position, and 
the 1945–1965 birth cohort is a grouping of individuals who share an age range.   
The risk to this cohort derives from previously unregulated health care and 
transfusion practices (Governance and Health Policy as found in the 
Socioeconomic and Political Context) and the poor understanding of HCV 
transmission risk that was present before the early 1990’s (Education as found in 
the Social Position).28,35  These components of an individual’s social position 
combine with the Socioeconomic and Political Context to form the Structural 
Determinants that lead to Intermediary Determinants of HCV transmission. 
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Intermediary Determinants include factors that more directly lead to HCV 
infection.  These include material circumstances, the cohesiveness of the 
surrounding community, the rates of HCV risk behaviors, and some medical 
conditions that may necessitate treatments associated with HCV exposure.  Drug 
use would also be a component of this population’s Intermediary Determinant 
Profile.  These factors interact with a health care system that can also be a risk 
for HCV transmission.  Health care transmission is possible from reused syringes 
and needles14,21 or from transfusions of infected blood, as used to occur before 
all donated blood was screened starting in 1992.6,17,28,34,43  Collectively, these 
Structural and Intermediary Determinants describe where HCV risks can lead to 
HCV infection, the health condition of concern for this study.     
 
Differences in Determinants between Cambodian and non-Cambodian 
Americans 
There are differences in Structural and Intermediary Determinants for HCV 
infected Cambodian Americans and non-Cambodian Americans.  Starting with 
Structural Determinants of a Socioeconomic and Political Context, Cambodian 
Americans’ HCV risks are influenced by Cambodian governance and polices and 
American governance and health policies.  A 2011 review of infection control 
standards in Cambodian hospitals and clinics noted inadequate training and poor 
adherence to World Health Organization (WHO) based protocols, and cleaning 
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protocols that did not meet sterilization standards.35  These practices confer HCV 
transmission risk to the Cambodian Americans who were subjected to them. 
For both groups, HCV risk is affected by American governance and health 
policies.  Before 1990, significant risk of HCV could be found in the transfusion of 
blood or clotting factor concentrates, in percutaneous exposure to reused 
needles for those receiving medical care, and in health care workers who were 
also at risk of percutaneous or mucosal exposure to HCV.  Subsequent infection 
control policies have since protected individuals in the US from these HCV risk 
factors.4,14,17,28   
The Social Position sets the stage for differences in HCV transmission 
because Determinants like gender or occupation affect social standing differently 
for Cambodian and non-Cambodian American individuals.  Compared to their 
male peers, Cambodian women have lower rates of literacy and lower levels of 
education.  Strong cultural norms dictate that they adhere to domestic roles and 
remain subordinate to men.12  A Cambodian woman could be at a higher risk of 
HCV transmission because of the vulnerable position dictated by this Structural 
Determinant of gender.  Other differences exist between the population groups in 
their Social Positions.  The level of education and occupation can also be higher 
overall for non-Cambodian Americans due to a greater level of comfort with the 
language and cultural norms of their home country. 
Regarding the 1945–1965 birth cohort, although non-Cambodian and 
Cambodian Americans may share this cohort risk, they come from different 
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Socioeconomic and Political Contexts.  These lead to different types of exposure 
risks and rates of exposure risks that are represented by this Social Position.   
The Intermediary Determinant that is most influential in HCV transmission 
is injection drug use.  Injection drug use has great relevance for HCV infection in 
the US.1,6,17,28,34,43   
Health Care Systems interact with Intermediary Determinants, and there 
are differences between health systems available to Cambodian and non-
Cambodian Americans.  Cambodians would have HCV risk concerns from 
traditional healing practices as well as Cambodian and American national health 
practices.  Non-Cambodians would not be seeking care from Cambodian 
traditional healing practices, and they would only experience HCV risk influences 
from American health care. 
The Solar and Irwin Conceptual Framework applied to HCV risks shows 
where these factors can occur in the social, economic, and political influences in 
population communities.  The Social and Political influences on Cambodian and 
non-Cambodian Americans are refined to describe risks for HCV.  How these 
influences differ in the strength of their effects can thus demonstrate differences 
in the rates of HCV risks in these population groups. 
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Methods  
	  
Study Design 
This is a cross sectional study of HCV infected adults tested for HCV 
between 2009 and 2012.  The group of interest, Cambodian HCV infected adults, 
is compared to a group of non-Cambodian HCV infected adults.   
Study Setting 
The city of Lowell, Massachusetts provides a rare opportunity to study in 
better detail the risk factors associated with HCV infection among Cambodian 
Americans.  The city has the second largest population of Cambodian Americans 
in the US,12,19 facilitating the study of risk factors in one focused area.  
Approximately 10,000 adult residents of the Lowell, Massachusetts 
community come to Lowell Community Health Center (LCHC) annually seeking 
primary care.  The community health center itself is divided into a number of 
clinics.  The major patient-oriented care clinics are Adult Medicine, Family 
Medicine, Pediatrics, Obstetrics-Gynecology and Family Planning, Behavioral 
Health, and the Metta Health Center, a clinic that focuses on Southeast Asian 
issues.  About 4000 of the patients seen annually at LCHC self-identify as 
Cambodian.   
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The system-wide medical records of LCHC are stored electronically using 
the eClinical Works software.  This format allows efficient review of patient visits, 
outside medical records, and laboratory and radiologic orders and reports.   
Study Sample 
 Figure 2 below shows how the study sample was collected. 
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Figure 2.  Flowchart 
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The initial sample for this study was drawn from 4,541 adults over the age 
of 18 years old who were tested for HCV at LCHC between January 1, 2009 and 
December 31, 2012.  Hepatitis C testing included HCV antibody or RNA virus 
labs.  This group of individuals included persons of all ethnicities, Cambodian 
and non-Cambodian. 
Of this preliminary group of 4,541 adults who were tested, demographic 
data was reviewed, and Cambodian ethnicity was confirmed in 1,581 individuals.  
The medical data of these 1,581 individuals was further reviewed and positive 
hepatitis C antibody or RNA test results were verified for 128 of these individuals, 
so they were included in the study as Cambodian American Hepatitis C infected 
adults. 
The rest of the 2,960 individuals tested for HCV were non-Cambodian 
Americans whose medical data was further reviewed to verify their hepatitis C 
diagnosis.  HCV infection was verified by positive laboratory testing in 541 
individuals, and they were included in the study as non-Cambodian American 
Hepatitis C infected adults. 
 
Variables of Interest 
Risk Factors 
 The primary outcome of this study was differences between Cambodian 
and non-Cambodian Americans in the risk factors for HCV transmission.  The 
risk factors used in this analyses included: 1) history of intravenous drug use, 2) 
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history of transfusions of blood products, 3) history of hemodialysis, 4) previous 
work in any healthcare field, 5) prior or current sexual partner with hepatitis C, 6) 
history of maternal infection with hepatitis C, and 7) year of birth between 1945 
and 1965.  The above outcome variables reflect the USPSTF recognized risk 
factors.28  These risk factors were documented in the Medical History, Problem 
List, and Social History sections of the electronic medical record.  The USPSTF 
recognized HCV risk factors of intranasal drug use, incarceration, and tattoos in 
unregulated settings were not included as outcome variables because their 
documentation in the medical records was poor. 
 
Patient Characteristics 
Patient characteristics abstracted from the medical record were: patient’s 
age at the time of hepatitis C testing, gender, need for translator service, overall 
drug use, chronic HCV infection, and, for Cambodians, their year of arrival to the 
US if available in the medical record.   
Chronic infections are defined as having persistent viremia for at least 6 
months.1,17,28,43  This was included in the study to allow a more complete 
evaluation of any differences in ALT abnormalities.  Individuals with verified HCV 
RNA in their blood were more likely to have hepatocyte injury detectable by ALT 
elevation compared to individuals who possibly cleared their acute HCV 
spontaneously in the past. 
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 The year of arrival to the US indicated how many years a Cambodian 
American individual was under the care of Cambodian health policies and 
medical care versus American health policies and medical care.  The need for 
translator service was evaluated because it described the level of language 
literacy, a detail that helped characterize these individuals’ Social Positions.   
 
Covariates 
 Data regarding a number of other potential covariates were also 
abstracted.  These covariates were the presence of HIV infection, alcohol use, 
and the presence of underlying liver disease that was documented with elevated 
aminotransferase levels on laboratory testing.   
 HIV is a listed HCV risk factor by AASLD/IDSA/IAS-USA and CDC 
guidelines “because of shared transmission modes”.1,28,43  HIV is closely 
associated with higher rates of injection drug use, transfusions, sexual exposure, 
and maternal exposure.23  HIV is not, however, considered a risk factor by the 
USPSTF.  For this reason, HIV infection was not considered an outcome variable 
as this study focused on USPSTF designated HCV risk factors.  HIV infection 
was documented as present if a positive HIV antibody test was found in that 
individual’s medical data and evaluated as a covariate that could confound 
findings about some outcome variables.  
 Alcohol use is not a risk factor for HCV transmission, but excessive 
alcohol use is associated with increased rates of recreational drug use.30  
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Increased rates of alcohol use could affect rates of the outcome variable of 
injection drug use, so excess alcohol use was considered a potential covariate in 
this study.  Alcohol use was defined as cases where the patient described a 
history of excessive alcohol use, or more than 14 drinks per week were 
documented, the weekly drink number that defines at-risk drinking.16,39 
Aminotransferase levels were measured with ALT (alanine 
aminotransferase) testing, the standard marker of liver injury for HCV infection 
and the marker specified in the AASLD guidelines.7,15  Hepatocyte injury 
measured by ALT elevation is a consequence of chronic HCV infection.9   As all 
individuals in the study have HCV, findings regarding ALT abnormalities would 
be an effect of that infection instead of a measure of HCV risk.  Thus, these 
measures were not evaluated as outcome variables because of concern that the 
ALT abnormality would be heavily influenced by the infection being studied.  
Instead, the ALT measurement is considered a covariate representing secondary 
causes of liver injury that could be associated with other outcome variables of 
interest.       
In this study, the level of hepatocyte injury was evaluated in two ways.  
The maximum recorded ALT test result for each study individual was collected, 
and these levels were averaged to be compared between the two study groups.  
The rates of maximum recorded ALT levels greater than 40IU/L were also 
compared between the study groups.  The ALT level of 40IU/L has been 
recognized as an upper limit for normal liver function by national groups.2,17,30   
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Data Analysis    
The data were organized in a Microsoft Excel spreadsheet, and basic 
statistics were performed with R statistical software.32  The frequencies of patient 
characteristics and risk factors were determined with Microsoft Excel and in SAS 
statistical software.33  Due to the small numbers in some of the risk factor 
categories, Fisher’s Exact Test and Welch’s T-test was used with R software to 
determine the significance of risk factor differences between the hepatitis C 
infected Cambodian Americans and non-Cambodian Americans.32 
Results 
Description of the study sample 
 Table 2 shows the study sample, comparing the Cambodian and non-
Cambodian populations. 
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Table 2. Patient Characteristics and Covariates (N=669 patients in care with HCV) 
   Cambodian (n=128) Non-Cambodian (n=541)  
Age 
 Mean   52.57   42.75  p<0.001 
 Standard dev  12.33   11.07 
 Minimum  19   19 
 Max   90   78 
 
Gender 
 Male   53 (41.4%)  360 (66.5%) p<0.001 
 Female   74 (57.8%)  181 (33.5%) 
 Transgender      1 (0.8%) 
 
Translator need 
 Yes   117 (91.4%)    75 (13.9%) p<0.001 
 No      11 (8.6%)  466 (86.1%) 
 Unknown          0 (0%)      0 (0%) 
 
Drug Use 
 Yes        3 (2.3%)  444 (82.1%) p<0.001 
 No   125 (97.7%)    97 (17.9%) 
 
HIV infection 
 Positive       4 (3.13%)    60 (11.09%) p=0.47 
 Negative    23 (17.97%)  212 (39.19%) 
 Untested  101 (78.91%)  269 (49.72%) 
 
Maximum ALT (IU/L)1 
 Mean     91.28   131.50  p=0.001 
 Stand dev    95.14   200.5 
 Minimum    14     14 
 Maximum  852   2052 
 Unknown      0       20 
 
ALT greater than 40 IU/L 
 Yes     93 (72.66%)  419 (77.45%) p=0.07 
 No     35 (27.34%)  103 (19.04%) 
 Unknown       19 (3.51%) 
 
Excessive Alcohol Use2 
 Yes     15 (11.7%)  217 (40.1%) p<0.001 
 No   110 (85.9%)  291 (53.8%) 
 Unknown     3 (2.3%)    33 (6.1%) 
 
1Single maximum ALT recorded, see page 16, Covariates 
2Any history of excessive alcohol use, see page 16, Covariates 
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In terms of patient characteristics, there were statistically significant 
differences between Cambodian and non-Cambodian Americans in these 
samples.  The average overall age of Cambodian adults in this study was 
significantly higher than the average age of non-Cambodian adults (52.6 vs. 42.8 
years, p<0.001).  (See Table 2 above)  The non-Cambodian HCV infected adults’ 
ages were distributed with a peak in the mid 30 year olds and another peak at 
the early 50 year olds.  (See Figure 3 in appendix) 
There were also statistically significant differences in the gender 
distributions in the sample groups.  Cambodian adults in this study were 58% 
women, 41% men, and 0.8% transgender women while the non-Cambodian 
group was composed of more men than women: 66.5% men and 33.5% 
women.   This difference in gender distributions between the two groups 
achieved statistical significance (p<0.001). 
There were significantly more Cambodian American adults that describe a 
need for a translator compared to the non-Cambodians in this study, 91.4% vs. 
13.9%, p<0.001.  The year of immigration to the US was reported in 91 cases.  
The year with the most arrivals was 2005, with most of these Cambodian 
Americans coming to the US between 2000 and 2005 (see Figure 4 in appendix). 
 
Risk Factors 
Table 3 shows the individual risk factors used in this study, comparing the 
Cambodian and non-Cambodian samples. 
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Table 3.  Risk Factors, Cambodian and Non-Cambodian 
 
Risk Factors Cambodian (n=128) non Cambodian (n=541)   
  Yes 
No or 
Unknown Yes 
No or 
Unknown   
Born between      
1945–1965 
85 
(66.4%) 
43 
(33.6%) 
241 
(44.5%) 
300 
(55.5%) 
p<0.001 
  
    
  
      
IV drug Use 
2 
(1.6%) 
126 
(98.4%) 
182 
(33.6%) 
359 
(66.4%) 
p<0.001 
  
    
  
Transfusion  
5 
(3.9%) 
123 
(96.1%) 
9 
(1.7%) 
532 
(98.3%) 
p=0.16 
  
    
  
Hemodialysis 
0 
(0%) 
128 
(100%) 
1 
(0.2%) 
541 
(99.8%) 
p>0.2 
  
    
  
History of 
work    In 
Health Care 
8 
(6.25%) 
120 
(93.8%) 
3 
(0.6%) 
538 
(99.4%) 
p<0.001 
  
    
  
Sexual 
exposure 
6 
(4.7%) 
122 
(95.3%) 
8 
(1.5%) 
533 
(98.5%) 
p=0.03 
  
    
  
Family history     
Maternal 
4 
(3.1%) 
124 
(96.8%) 
4 
(0.7%) 
537 
(99.3%) 
p=0.048 
  
    
  
  
    
  
One or more 
Risk factors 
97 
(75.8%) 
31 
(24.2%) 
371 
(68.6%) 
170 
(31.4%) 
p=0.13 
  
    
  
Two or more     
Risk factors 
15 
(11.7%) 
113 
(88.3%) 
117 
(21.6%) 
424 
(78.4%) 
p=0.01 
    
    *The response “U” for “Unknown” was used if there was no indication the individual had 
been asked about the risk factor or if no history of the presence or absence of this risk 
factor was available. 
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There were statistically significant differences in the rates of injection drug 
use in Cambodian and non-Cambodian individuals (1.6% vs. 33.6%, p<0.001, 
see Table 3).  There were also significantly more HCV-infected Cambodian 
adults born between 1945 and 1965 than non-Cambodians (66.4% vs. 44.5%, 
p<0.001).   
Prior health care work, sexual exposure, and maternal history of infection 
were reported in small numbers of individuals, but there were statistically 
significant findings for these risk exposures.  For employment in health care, 
significantly more Cambodians reported this history (6.25% vs. 0.6%, p<0.001).  
Significantly more Cambodian adults also reported a sexual exposure to HCV 
(4.7% vs. 1.5%, p=0.034) and a maternal history of HCV infection (3.1% vs. 
0.7%, p=0.048).  Rates of transfusion were greater in Cambodian Americans, but 
this finding did not achieve statistical significance (3.9% vs. 1.7%, p=0.159).  
Rates of hemodialysis were negligible and equivalent between the study groups 
(0% vs. 0.2%, p=1.0).   
Significantly more non-Cambodian Americans had two or more HCV risk 
factors, but there was no statistically significant difference between Cambodians 
and non-Cambodians with one or more risks (68.6% vs. 75.8%, p=0.13).  The 
factors considered for this calculation were the outcome variables described: 
intravenous drug use, birth between 1945 and 1965, history of transfusion, 
history of hemodialysis, healthcare employment, sexual exposure, and maternal 
history of HCV.  None of the Cambodians with two or more risk factors had a 
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history of injection drug use, and 93.3% had the birth cohort as one of the 
multiple risk factors.   
As noted above, rates of individuals that had one or more risk factors were 
not significantly different between the study groups.  Among individuals with one 
or more risk factors, significantly more Cambodian Americans were born 
between 1945 and 1965 (87.6% vs. 62.9%, p<0.001) and significantly more non-
Cambodian Americans reported intravenous drug use in their past (49.1% vs. 
2.1%, p<0.001).   
 
Covariates 
Cambodian adults with HCV had lower rates of HIV infection, but this 
difference did not achieve statistical significance (3.13% vs. 11.09%, p=0.469).  
Many adults in the Cambodian group were never tested for HIV, and only 27 
individuals have any test result for this condition.   
The average ALT was significantly greater in non-Cambodian than in 
Cambodian individuals (132 IU/L vs. 91 IU/L, p=0.001).  More non-Cambodian 
individuals had ALT levels greater than 40 IU/L, a finding that approached but did 
not achieve statistical significance (72.66% vs. 77.45%, p=0.07).  Significantly 
more non-Cambodians had chronic HCV infection than Cambodians (73.75% vs. 
53.13%, p<0.001). 
Rates of alcohol use were significantly higher for non-Cambodian adults 
than for Cambodian adults, 40.1% compared to 11.7%.  This difference was 
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statistically significant.  There was a high rate of documentation for this 
characteristic as information regarding this behavior was present for 94% to 
almost 98% of the individuals (data not shown).  
Discussion 
 
Major Risk Factors 
Injection drug use was not a major HCV risk factor for infected 
Cambodians seen at LCHC between 2009 and 2012.  Studies of HCV infected 
Asian Americans have not included many Cambodian Americans, so no 
conclusions could be made about the low rates of injection drug use found in 
Cambodians.11,14,21,22,37  Unlike those studies, Cambodian Americans were well 
represented here, and fewer than 2% of the HCV infected Cambodian Americans 
seeking care at LCHC had any history of injection drug use.  This finding was 
significant and profound.   
One explanation for the lack of injection drug use was seen in a graph of 
Cambodian individuals’ ages side by side with non-Cambodians (Figure 4).  In 
Massachusetts, the increase in injection drug use-associated with hepatitis C 
infection has been associated with 15–24 year olds, suggesting that 20–30 year 
old non-Cambodians also contributed strongly to injection drug use rates in 
Lowell.29  Unlike the non-Cambodian Americans, HCV infected Cambodian 
Americans in this study included very few 20–30 year olds.  The Cambodian 
group did not include any of these younger individuals for whom HCV 
29 
	  
	  
transmission would have occurred through injection drug use.   
Instead of injection drug use, the predominant risk factor for Cambodians 
in this study was birth between 1945 and 1965.  This study was first planned at 
the end of 2012, the same year that CDC Morbidity and Mortality Weekly Report 
(MMWR) publications recognized increased HCV in this birth cohort.34  The ages 
of individuals in this study were collected as important patient characteristics, but 
it was not anticipated that one group’s older age profile would become a 
designated risk factor during the course of the study.  Many Cambodian 
individuals had only this birth cohort as a risk factor of significance (86.7%).  This 
also means that no identifiable risk behavior explained why almost 87% of the 
Cambodian individuals acquired hepatitis C.  The US risk factor guidelines did 
not seem appropriate to describe transmission risk in this population of 
Cambodian Americans. 
For Cambodians in this birth cohort, percutaneous exposures to HCV may 
have occurred through Cambodian medical care or traditional health practices.  
Although there are no exact numbers to demonstrate how many Cambodians in 
this study received medical care in Cambodia, it can be surmised that this 
exposure was more likely in those who came to the US recently, after 2000 (see 
Figure 4).  For these individuals, most of their lives were lived in Cambodia, not 
in the US, suggesting HCV exposure likely occurred before their arrival in the US.  
Most specific risk factors, namely transfusions, dialysis, health care work, sexual 
exposure, or maternal infection, were reported in small numbers.  It was difficult 
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to attribute HCV infection to these exposures.  The descriptions of risk factors in 
the US were thus not adequate for the risks to which the Cambodian Americans 
in this study were exposed.  
Multiple Risk Factors 
There was no significant difference in the rates of individuals with one or 
more HCV risk factors, but significantly more non-Cambodians had two or more 
HCV risk factors.  For these categories of one or more and two or more risks, 
Cambodians and non-Cambodians showed significantly different rates of 
injection drug use and birth cohort risk.  Cambodians with one or more risk 
factors had significantly higher rates of birth cohort risk, a finding consistent with 
the older average age in the Cambodian group.  Non-Cambodians had 
significantly higher rates of injection drug use. 
Unlike the direct percutaneous HCV risk of injection drug use, the birth 
cohort risk does not offer an explanation for the blood or bodily fluid exposure 
that led to HCV for this study’s Cambodian Americans.  Possible contributors to 
HCV for Cambodians in this birth cohort may have included traditional healing 
practices or routine care in Cambodian health care facilities.  For example, use of 
unsterilized reused needles for acupuncture or other medical care could transmit 
HCV in any setting where regulation of these practices is poor.  Other studies of 
Asian Americans have speculated but did not prove that traditional healing 
practices may contribute to HCV transmission.14,21  These studies did not include 
Cambodians in large numbers.  Recent reviews of infection control practices in 
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Cambodian health care facilities show that transmission from inadequately 
sterilized medical equipment remains a risk.20  Neither traditional healing 
practices or medical care abroad are nationally recognized risk factors for HCV 
transmission, but they may contribute to the increase HCV risk from birth 
between 1945 and 1965 for these Cambodian Americans.  This differs greatly 
from the US where HCV risk from unhygienic medical practices has diminished 
greatly due to effective infection control practices.14  A larger study of invasive 
medical procedures received by immigrants prior to their arrival in the US could 
potentially clarify any association with HCV infection but was outside the scope of 
this study.   
 
Other Considerations 
Non-Cambodian Americans had significantly higher rates of excess 
alcohol use and a higher average maximum ALT.  Regarding rates of elevated 
ALT levels, there was no significant difference between Cambodians and non-
Cambodians (72.66% vs. 77.45%, p=0.07).  This indicated that non-Cambodian 
Americans had higher ALT elevations than Cambodian Americans.  Significantly 
more non-Cambodian Americans also described high levels of alcohol use and 
had chronic infection.  Non-Cambodian Americans may have had greater 
laboratory evidence of hepatocyte injury more frequently because of higher rates 
of underlying alcohol use and chronic HCV.  Non-Cambodians may have had 
damage from a combination of liver conditions more frequently than Cambodian 
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Americans. 
 There was no significant difference between the study groups in rates of 
HIV infection.  HIV infection, then, was unlikely to have been a confounder for the 
differences found in rates of injection drug use and birth cohort.  
Limitations of the study 
 There were potential limitations of this study, starting with the difference in 
gender and age profiles between the Cambodian and non-Cambodian groups of 
patients.  The probability of an individual experiencing a specific HCV risk factor 
could be very different for a man than for a woman or for an older rather than a 
younger individual.  The Cambodian group was significantly older and with 
significantly more women.  This great difference could potentially influence the 
rates of risk factors that were found, a possible limitation to the study.  A decision 
was made not to select for an age and gender matched group of non-
Cambodians to compare with the HCV infected Cambodian Americans.  Attempts 
to match these groups for age by trying to randomly select out older individuals 
from the Cambodian group would have erased this study’s finding that the 1945–
1965 birth cohort was a major risk factor for this population.  It was instead 
recognized that these study populations, as gathered, provided the entirety of 
confirmed HCV infected Cambodian and non-Cambodian Americans seen at 
LCHC from 2009 to 2012.  By not attempting to better match the study groups, a 
more accurate comparison was made of all HCV infected Cambodian individuals 
with all non-Cambodian hepatitis C infected adults during this 4 year period of 
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time.    
Injection drug use was possibly under-reported in this study, but this did 
not serve as a significant limitation.  Instead, any possible under-reporting 
strengthened this study’s findings.  Statewide, Massachusetts reported an 
injection drug use rate of 72%.42  In comparison, the 34% rate of injection drug 
use (p<0.001) found in these non-Cambodians was unexpectedly low for the 
area.  Under-reported injection drug use among non-Cambodians would then 
suggest an even greater difference between Cambodians and non-Cambodians 
than what was found in this study.  Additionally, the injection drug use rate for 
Cambodians in this study is consistent with the 3–11% rate in other studies of 
HCV risk factors in Asian Americans.14,21  Any potential under-reporting seemed 
to affect the non-Cambodian group more than the Cambodian group; thus, the 
large and significant difference in injection drug use rates between the two 
groups indicated that this finding was at least as great as what was reported in 
this study, if not more. 
Another potential study limitation was incomplete data reporting, a 
frequent concern about recall bias in any medical data review.8  Many of the risk 
factors for HCV transmission included socially stigmatized behaviors that people 
may not have been comfortable discussing or medical exposures that individuals 
may not have been able to recall accurately.  In this study, use of the same 
electronic medical data for both groups and care of all patients by the same 
medical staff minimized the potential of one group being affected more than the 
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other.  This likely reduced the chance of bias.  
Incomplete data documentation can lead to the exclusion of cases with 
HCV tests that were done but not documented. The effects of incomplete medical 
data on case exclusion may have affected the study’s findings with inaccurate 
reporting.  Rigorous inclusion criteria, however, was needed to insure that the 
HCV diagnoses were accurate.  Applying the same selection criteria to both 
groups again reduced potential bias. 
Incomplete data documentation can also affect the reporting of any of the 
risk factors and covariates studied.  Again, care of both study groups by the 
same medical staff and documentation in the same electronic medical record 
likely reduced the possibility of this bias affecting one group more than the other. 
Consequences of Inadequate Risk Identification 
Failure of the recognized HCV transmission risks to adequately describe 
infection compromised medical care for this population.  Although previous 
guidelines did not recommend screening for HCV infection, this type of testing is 
now indicated for those born between 1945 and 1965 because of the availability 
of new, more effective treatment.28  These same guidelines suggested these 
individuals in the 1945–1965 birth cohort were infected in the past.28  However, if 
currently recognized HCV risk factors did not adequately describe HCV 
transmission for the Cambodian Americans in this study or for adults born 
between 1945 and 1965, this inadequate description of HCV risk suggested that 
other individuals may have been at risk unknowingly.  This compromises the 
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health of a population and lends significance to the need for better recognition of 
HCV risk factors.   
HCV risks that are poorly understood can have an impact beyond an 
ongoing risk of infection. Testing in a healthcare setting is triggered by the 
presence of previously recognized risk factors. Although some of the current 
national guidelines recommend baseline screening of all those born between 
1945 and 1965, it is more likely that a person will be tested for hepatitis C if the 
health care worker feels the individual is at risk.  The absence of known risk 
factors can be a barrier to screening if the HCV risk is unrecognized.     
Areas for Further Study 
Potential areas of further study include more detailed inquiry of 
Cambodian American individuals at LCHC as well as a larger inquiry of 
Cambodian Americans in the community and in the US regarding medical 
procedures, percutaneous exposures, family and sexual exposures that might 
have contributed to their HCV infection.  Intravenous drug use is the predominant 
risk factor in the US,3,27,42 but there remains the possibility that certain pockets of 
the American population, such as this Cambodian American population in Lowell, 
may have different, previously unrecognized risk factors or forms of the above 
risk factors that are not immediately familiar to the health professionals providing 
their care.   
Another area of study would be the evaluation of HCV infection rates in 
younger Cambodian Americans at LCHC.  In Massachusetts, injection drug use 
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in 15–24 year olds contributes strongly to HCV infection.29  HCV screening for 
younger Cambodian Americans would better assess infection rates in 
Cambodians less than 30 years old.  This would assess the accuracy of this 
study’s findings that few Cambodian individuals 20–30 years old have HCV 
infection.   
Conclusion 
 
 Hepatitis C is a potentially devastating chronic viral infection.  However, 
the predominant HCV risk factor in this group of Cambodian Americans in Lowell, 
Massachusetts does not seem to be intravenous drug use, the major risk factor 
nationally and for the non-Cambodian Americans in this study.  This is a novel 
finding for Cambodian Americans.  The major risk factor for Cambodian 
Americans in this study is, instead, the large number of individuals born between 
1945 and 1965.  Aside from this birth cohort, however, there is no clear, major 
risk factor present in this Cambodian American population to explain their HCV 
infection.  A lack of recognizable HCV risk factors can affect the perception of 
any need for HCV testing.  This serves as a potential barrier to care for 
Cambodian Americans and could continue to place Cambodian Americans and 
older adults at risk of HCV infection if their risks are not well understood.   
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Appendix 
 
 
Figure 3. Distribution of ages at the time of HCV testing 
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Figure 4.  Years of Arrival to the United States among Cambodian hepatitis C 
infected adults 
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